In a nutshell This study compared the effectiveness and safety of tirzepatide to insulin degludec (Tresiba) in patients with uncontrolled type 2 diabetes (T2D). The data showed that tirzepatide produced better blood glucose control and body weight improvements with reduced risk of hypoglycemia, compared to degludec in these patients. Some...
Read More
In a nutshell This study compared the effect of administering 1.5 mg, 3 mg, and 4.5 mg of dulaglutide (Trulicity) on overall bodyweight reduction in patients with type 2 diabetes (T2D). The authors concluded that higher doses of dulaglutide caused more weight loss in these patients. Some background Abnormal or excessive levels of fat in the...
Read More
In a nutshell In this study, the authors evaluated the effectiveness of adding dapagliflozin (Farxiga) to insulin therapy in patients with uncontrolled type 2 diabetes (T2D). The study showed that compared to increasing insulin doses, dapagliflozin improved glucose control while reducing weight and hypoglycemia (dangerously low blood...
Read More
In a nutshell This study compared the risk of hypoglycemia (dangerously low blood glucose levels) for insulin glargine 300 U/ml (Gla-300; Toujeo) and standard-of-care basal insulin (SOC-BI) at patients with type 2 diabetes (T2D) with risk factors for hypoglycemia. It found that Gla-300 was associated with a lower risk of hypoglycemia than...
Read More
In a nutshell This study looked at the use of omarigliptin (Marizev) in insulin-treated patients with uncontrolled type 2 diabetes (T2D). It found that omarigliptin was well-tolerated and improved blood glucose control. Some background Type 2 diabetes (T2D) is usually treated initially with diet, exercise, and...
Read More
In a nutshell This study tested the ability of henagliflozin (SHR3824) in controlling blood glucose levels in patients with type 2 diabetes (T2D). The authors found that henagliflozin alone was able to control glucose levels, reduce body weight and blood pressure in these patients. Some background Insulin is a hormone produced by the...
Read More
In a nutshell This study compared weekly semaglutide (Ozempic) and daily sitagliptin (Januvia) for type 2 diabetes (T2D) in an Asian population. It showed that patients treated with semaglutide had a greater improvement in T2D control and increased weight loss compared to those treated with sitagliptin. Some...
Read More
In a nutshell This study compared the safety of two medications, linagliptin (Trajenta) and glimepiride (Amaryl). It found that the medications had the same risk of heart attack, stroke, or heart-related death, while linagliptin was associated with a lower risk of hypoglycemia (dangerously low blood glucose level). Some background There...
Read More
In a nutshell This controlled trial looked at adding exenatide (Byetta) to intensive insulin treatment for patients with type 2 diabetes (T2D) who still had high blood sugar. It found that the exenatide improved blood sugar control and reduced body weight in these patients. Some background T2D is a metabolic condition in which the body does not...
Read More
In a nutshell This study compared two doses of dapagliflozin (Farxiga) to a placebo to determine how effective and safe they were long-term for patients with uncontrolled type 1 diabetes (T1D). The results showed that both doses were able to reduce blood glucose levels and body weight but increased the risk of ketoacidosis. Some background...
Read More
In a nutshell This study compared the effectiveness and safety of evogliptin (Suganon) to another non-insulin drug, linagliptin (Tradjenta), in patients with type 2 diabetes (T2D). The results showed that evogliptin was as safe and effective at reducing patients’ blood glucose levels as linagliptin. Some background Several treatment options...
Read MoreIn a nutshell This study compared the safety and effectiveness of semaglutide (Ozempic) and canagliflozin (Invokana) for patients with uncontrolled type 2 diabetes (T2D). The authors found that semaglutide more effectively reduced blood glucose levels and body weight than canagliflozin. Some background Often, patients with T2D are given...
Read More
